At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit

Could Signal First Tremelimumab Approval

 
• By Andrew McConaghie
  
AstraZeneca
While Tagrisso is a market leader in targeted NSCLC treatment, AZ's immuno-oncology franchise lags behind other competitors.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip